What is Amgen's revenue?

Amgen (AMGN) generated $37.2B in revenue over the trailing twelve months, up 9.1% year over year.

Amgen reported $7.8B in net income over the trailing twelve months, a 21.0% net margin.

What are Amgen's profit margins?

Gross margin is 68.3% and operating margin is 28.4%, with a 21.0% net margin.

What is Amgen's earnings per share?

Amgen's diluted EPS over the trailing twelve months is $14.38.

Where does Amgen's income statement data come from?

Every line is extracted from Amgen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Amgen AMGN Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$37.22B+9.1%	$36.75B+10.0%	$35.97B+10.6%	$34.92B+12.9%	$34.13B+15.6%
Total cost of revenue	$11.81B-6.4%	$12.04B-6.4%	$12.17B-5.3%	$12.4B+9.2%	$12.63B+27.1%
Gross profit	$25.41B+18.2%	$24.71B+20.2%	$23.8B+20.9%	$22.52B+15.0%	$21.5B+9.7%
Gross margin	68.3%+5.3pp	67.2%+5.7pp	66.2%+5.7pp	64.5%+1.2pp	63%-3.4pp
Research and development	$7.51B+22.9%	$7.27B+21.9%	$6.85B+18.7%	$6.4B+18.5%	$6.11B+20.5%
Selling, general and administrative	$6.97B-0.1%	$7.05B-0.6%	$6.98B-6.9%	$6.88B-4.7%	$6.98B+3.7%
Depreciation and amortization	$4.9B-12.3%	$5.17B-7.6%	$5.43B-2.6%	$5.52B+8.8%	$5.58B+22.1%
Total costs & expenses	$26.65B-0.1%	$27.67B+5.8%	$27.3B+3.7%	$26.73B+8.0%	$26.68B+18.2%
Operating income	$10.57B+41.9%	$9.08B+25.1%	$8.67B+39.4%	$8.19B+32.3%	$7.45B+6.9%
Operating margin	28.4%+6.6pp	24.7%+3.0pp	24.1%+5.0pp	23.5%+3.4pp	21.8%-1.8pp
Interest expense	$2.69B-12.0%	$2.76B-12.7%	$2.85B-11.8%	$2.94B-8.5%	$3.05B-3.2%
Other income (expense), net	——	——	——	——	——
Income before income taxes	$9.09B+36.6%	$8.98B+94.7%	$8.24B+76.2%	$7.42B+111%	$6.65B+53.0%
Income tax expense	$1.29B+79.5%	$1.27B+144%	$1.24B+176%	$805M+104%	$717M+23.2%
Net income	$7.8B+31.5%	$7.71B+88.5%	$7.01B+65.6%	$6.62B+111%	$5.93B+57.7%
Net margin	21%+3.6pp	21%+8.7pp	19.5%+6.5pp	19%+8.8pp	17.4%+4.6pp
Diluted earnings per share	$14.38+31.2%	$14.24+88.6%	$12.94+65.5%	$12.23+110%	$10.96+56.3%
Basic earnings per share	$14.48+31.0%	$14.33+88.1%	$13.03+65.1%	$12.32+111%	$11.05+57.0%
Weighted-average shares, diluted	2.2B+0.2%	2.2B+0.3%	2.2B+0.4%	2.2B+0.6%	2.2B+0.7%
Weighted-average shares, basic	2.2B+0.2%	2.2B+0.2%	2.2B+0.3%	2.2B+0.3%	2.1B+0.4%
Impairment of Intangible Assets	——	——	——	——	$891M+26.2%
Other Non-Cash Income (Expense)	-$132M—	-$149M—	$139M—	——	——
Unrealized Gain (Loss) on Investments	——	——	——	——	$1.65B—
Deferred and other income taxes	-$647M+39.9%	-$721M+41.3%	-$1.04B+31.7%	-$1.12B+39.8%	-$1.08B+33.7%
Accounts payable	——	——	——	——	——
Increase (Decrease) in Accounts Receivable	$1.18B—	$2.9B—	$1.35B—	$1.69B—	——
Increase Decrease In Accrued Income Taxes Payable	——	——	——	——	——
Accrued liabilities	$414M+52.2%	$499M+442%	$478M+92.7%	$403M—	$272M—
Increase (Decrease) in Inventories	-$616M+69.4%	-$886M+65.0%	-$1.09B+60.8%	-$1.53B+25.2%	-$2.01B-48.6%
Long-term tax liabilities	$312M—	$311M—	——	——	——
Increase (Decrease) in Other Operating Assets	$1.06B+38.5%	$1.27B+94.3%	$704M-19.1%	$720M-13.7%	$764M—
Other liabilities	-$161M—	-$164M—	——	——	——
Accrued sales incentives and allowance	——	——	$2.96B+180%	$2.7B+632%	$2B+95.5%
Debt	$2.69B-12.0%	$2.76B-12.7%	$2.85B-11.8%	$2.94B-8.5%	$3.05B-3.2%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$5.32B+55.0%	-$10.86B-15.3%	-$11.04B-110%	-$11.84B—	-$11.81B—
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$2.21B-73.4%	-$1.94B-85.8%	-$1.65B+94.0%	-$1.45B—	-$1.28B—
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$10.76B-11.8%	$9.96B-13.3%	$13.13B+80.9%	$12.01B+86.4%	$12.19B+50.6%
Other Noncash Income (Expense)	-$132M—	-$149M—	$139M—	——	——
Other Nonrecurring Income Expense	——	——	——	——	——
Payment for (Proceeds from) Other Investing Activity	——	——	——	——	——
Payments of Ordinary Dividends, Common Stock	$5.2B+6.1%	$5.12B+6.0%	$5.05B+5.9%	$4.97B+5.9%	$4.9B+6.0%
Payments to Acquire Property, Plant, and Equipment	$2.16B+69.1%	$1.86B+69.5%	$1.59B+62.9%	$1.41B+45.9%	$1.28B+28.0%
Debt issued (Note 13)	——	——	——	——	$0-100%
Financing — other	——	——	——	-$121M—	-$69M—
Repayments of Long-Term Debt	$3.33B-45.4%	$5B+38.9%	$5B—	$5.7B—	$6.1B—
Research and development expense	$7.51B+22.9%	$7.27B+21.9%	$6.85B+18.7%	$6.4B+18.5%	$6.11B+20.5%
Revenue From Contract With Customer Excluding Assessed Tax	$37.22B+9.1%	$36.75B+10.0%	$35.97B+10.6%	$34.92B+12.9%	$34.13B+15.6%
Stock-based compensation	$484M-5.5%	$494M-6.8%	$503M-9.7%	$512M-2.5%	$512M+5.1%
EBIT	$10.57B+41.9%	$9.08B+25.1%	$8.67B+39.4%	$8.19B+32.3%	$7.45B+6.9%
EBITDA	$15.46B+18.7%	$14.25B+10.9%	$14.1B+19.6%	$13.71B+21.7%	$13.03B+12.9%
EBITDA	$15.46B+18.7%	$14.25B+10.9%	$14.1B+19.6%	$13.71B+21.7%	$13.03B+12.9%
EBITDA margin	41.5%+3.4pp	38.8%+0.3pp	39.2%+3.0pp	39.3%+2.9pp	38.2%-0.9pp
EBIT	$10.57B+41.9%	$9.08B+25.1%	$8.67B+39.4%	$8.19B+32.3%	$7.45B+6.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Amgen.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amgen's revenue?: Amgen (AMGN) generated $37.2B in revenue over the trailing twelve months, up 9.1% year over year.
Is Amgen profitable?: Amgen reported $7.8B in net income over the trailing twelve months, a 21.0% net margin.
What are Amgen's profit margins?: Gross margin is 68.3% and operating margin is 28.4%, with a 21.0% net margin.
What is Amgen's earnings per share?: Amgen's diluted EPS over the trailing twelve months is $14.38.
Where does Amgen's income statement data come from?: Every line is extracted from Amgen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.